Page 115 - GHES-2-4

Global Health Economics and
Sustainability
Cost-effectiveness of oral semaglutide in Greece

Table 7. Probabilistic sensitivity analysis results
Treatment targets Oral semaglutide 14 mg (mean Empagliflozin 25 mg (mean cost Difference (Mean cost of
cost of control [CI 95%]) (EUR) of control [CI 95%]) (EUR) control [CI 95%]) (EUR)
Achieved in PIONEER 2
HbA1c ≤6,5% 2,558.47 (2,313.36 – 2,850.67) 2,454.98 (2,047.4 – 2,997.39) 103.49 (−495.62 – 606.67)
HbA1c ≤7% 1,831.20 (1,707.12 – 1,967.55) 1,225.85 (1,095.43 – 1,384.94) 605.35 (410.22 – 794.31)
≥1%-point HbA1c reduction 1,914.62 (1,776.85 – 2,067.12) 1,242.45 (1,109.10 – 1,398.39) 672.17 (465.14 – 874.57)
HbA1c <7% without hypoglycemia 2,174.04 (1,992.41 – 2,380.76) 1,359.27 (1,202.53 – 1,545.66) 814.77 (557.55 – 1,074.42)
and no weight gain
Weight loss ≥5% 3,004.16 (2,669.60 – 3,400.19) 1,353.62 (1,200.22 – 1,537.25) 1,650.54 (1,270.70 – 2,086.01)
Weight loss ≥10% 8,174.05 (6,501.18 – 10,529.62) 6,973.94 (5,014.36 – 10,303.43) 1,200.11 (−2,564.61 – 4,338.69)
≥1%-point HbA1c reduction and 2,844.78 (2,540.64 – 3,215.34) 2,015.04 (1,712.19 – 2,406.99) 829.73 (323.97 – 1,313.93)
weight loss ≥3%
Achieved in PIONEER 3
HbA1c ≤6.5% 3,613.00 (3,173.43 – 4,151.45) 1,952.22 (1,549.32 – 2,526.48) 1,660.78 (939.35 – 2,356.74)
HbA1c ≤7% 2,213.42 (2,036.72 – 2,415.21) 828.07 (723.96 – 957.48) 1,385.35 (1,167.52 – 1,611.25)
≥1%-point HbA1c reduction 2,085.84 (1,932.53 – 2,261.11) 694.87 (618.00 – 790.32) 1,390.96 (1,209.35 – 1,582.54)
HbA1c <7% without hypoglycemia 2,699.76 (2,442.03 – 2,997.96) 1,319.82 (1,097.98 – 1,608.06) 1,379.94 (992.33 – 1,755.92)
and no weight gain
Weight loss ≥5% 3,594.87 (3,168.27 – 4,118.14) 2,324.69 (1,801.89 – 3,105.47) 1,270.17 (373.22 – 2,024.59)
Weight loss ≥10% 11,183.28 (8,661.38 – 14,973.42) 11.925.84 (6,597.16 – 24,481.59) −742.56 (−13,783.15 – 6,117.98)
≥1%-point HbA1c reduction and 3,217.72 (2,861.34 – 3,644.12) 2,271.87 (1,783.89 – 2,983.11) 945.85 (150.48 – 1.608.65)
weight loss ≥3%
Achieved in PIONEER 4
HbA1c ≤6.5% 2,807.89 (2,463.68 – 3,225.66) 4,858.40 (4,125.04 – 5,844.40) 2,050.51 (3,088.36 – 1,203.21)
HbA1c ≤7% 1,998.55 (1,818.28 – 2,206.44) 2,873.78 (2,582.82 – 2,224.35) 875.24 (1,265.36 – 518.05)
≥1%-point HbA1c reduction 2,071.91 (1,877.91 – 2,300.32) 3,082.29 (2,753.74 – 3,472.38) 1,010.38 (1,458.79 – 608.40)
HbA1c <7% without hypoglycemia 2,152.31 (1,941.63 – 2,390.42) 3,273.27 (2,904.20 – 3,715.13) 1,120.95 (1,616.56 – 681.94)
and no weight gain
Weight loss ≥5% 2,715.15 (2,384.81 – 3,107.44) 6,501.66 (5,316.08 – 8,120.02) 3,786.51 (5,442.34 – 2,557.33)
Weight loss ≥10% 7,545.44 (5,799.37 – 10,110.13) 22,388.14 (14,916.07 – 36,736.22) 14,842.71 (29,228.28 – 7,042.28)
≥1%-point HbA1c reduction and 2,786.81 (2,447.73 – 3,214.02) 5,555.85 (4,633.53 – 6,809.92) 2,769.04 (4,046.21 – 1,766.97)
weight loss ≥3%
Abbreviation: HbA1c: Hemoglobin A1C.

Figure 8. Cost-effectiveness acceptability curve of oral semaglutide 14 mg versus empagliflozin based on PIONEER 2. Figure created using Microsoft Excel

Volume 2 Issue 4 (2024) 8 https://doi.org/10.36922/ghes.3032